NewsBenzinga报告称，艾伯维的 SKYRIZI 在克罗恩病中显示出持续至 144 周的内镜结局，且五年时瘘管消退率达 74.5%；同时，RINVOQ 真实世界数据显示晚期克罗恩病可实现缓解 报告称，艾伯维的 SKYRIZI 在克罗恩病中显示出持续至 144 周的内镜结局，且五年时瘘管消退率达 74.5%；同时，RINVOQ 真实世界数据显示晚期克罗恩病可实现缓解 Benzinga 2026.10.12 07:03 (GMT+0) Open on Benzinga Other news Bitmine Immersion Technologies (BMNR) Announces ETH Holdings Reach 6.04 Million Tokens, and Total Crypto and Total Cash & Marketable Securities Holdings of $15.1 Billion Piper Sandler Maintains Overweight on Halliburton, Lowers Price Target to $42 Eos Energy Enterprises Now Expects FY26 Revenue In Lower Half Of Its $300M To $350M Range CME Group Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call Dan Ives Says Meta, SpaceX and Tesla Face Big Questions This Week — His 3 'Big Focus Points' Ahead of Tech Earnings Mizuho Maintains Outperform on Equifax, Lowers Price Target to $185
Bitmine Immersion Technologies (BMNR) Announces ETH Holdings Reach 6.04 Million Tokens, and Total Crypto and Total Cash & Marketable Securities Holdings of $15.1 Billion
CME Group Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call
Dan Ives Says Meta, SpaceX and Tesla Face Big Questions This Week — His 3 'Big Focus Points' Ahead of Tech Earnings
